Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Venetoclax in Mantle Cell Lymphoma

February 16th 2021

Dr. Jain on the Efficacy of Ibrutinib/Rituximab in MCL

February 15th 2021

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib plus rituximab in mantle cell lymphoma.

Dr. Ruan on the Long-Term Benefits of Lenalidomide/Rituximab in MCL

February 12th 2021

Jia Ruan, MD, PhD, discusses the long-term benefits of lenalidomide plus rituximab in mantle cell lymphoma.

Dr. Mehta on the Rationale for Utilizing Parsaclisib in Relapsed or Refractory MCL

February 12th 2021

Amitkumar Mehta, MD, discusses the rationale behind utilizing parsaclisib in relapsed or refractory mantle cell lymphoma as part of the phase 2 CITADEL-205 study.

BTK Inhibitors for Relapsed MCL: Important Considerations

February 9th 2021

Selecting a BTKi for Relapsed MCL Treatment

February 9th 2021

Acalabrutinib and Zanubrutinib for Relapsed MCL

February 2nd 2021

BTK Inhibitors for Relapsed Mantle Cell Lymphoma

February 2nd 2021

Lenalidomide and Bortezomib for Mantle Cell Lymphoma

January 26th 2021

Go-To Treatment Regimens in Mantle Cell Lymphoma

January 26th 2021

Treatment Approaches in Mantle Cell Lymphoma

January 19th 2021

Accurately Diagnosing Mantle Cell Lymphoma

January 19th 2021

Interrupting Venetoclax Triplet After MRD Negativity Is Feasible in Relapsed/Refractory Mantle Cell Lymphoma

January 12th 2021

January 12, 2021 - Stopping combination treatment with venetoclax, lenalidomide, and rituximab after achieving minimal residual disease negativity in patients with relapsed/refractory mantle cell lymphoma is feasible.

Dr. Lee on the Tolerability of Ibrutinib/Cirmtuzumab in MCL and CLL

January 8th 2021

Hun Ju Lee, MD, discusses the tolerability of ibrutinib plus cirmtuzumab in mantle cell lymphoma and chronic lymphocytic lymphoma.

Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCL

January 8th 2021

Brexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.

MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval

January 6th 2021

James Gerson, MD, discusses the introduction of CAR T-cell therapy to the mantle cell lymphoma armamentarium and how induction therapy followed by stem cell transplant has maintained a role.

Dr. Ruan on Updated Results With Lenalidomide/Rituximab in MCL

January 4th 2021

Jia Ruan, MD, PhD, discusses updated results with the combination of lenalidomide and rituximab in mantle cell lymphoma.

Dr. Jain on the Responses Elicited With Ibrutinib/Rituximab in Previously Untreated MCL

December 24th 2020

Preetesh Jain, MD, PhD, discusses the efficacy of ibrutinib and rituximab in elderly patients with previously untreated mantle cell lymphoma.

Dr. Lee on the Safety, Efficacy of Cirmtuzumab/Ibrutinib Combo in MCL

December 24th 2020

Hun Ju Lee, MD, discusses responses to cirmtuzumab plus ibrutinib in patients with mantle cell lymphoma.

Early MRD Monitoring in Younger Patients With MCL Posttransplant Predicts Outcomes

December 22nd 2020

December 22, 2020 - Minimum residual disease negativity in the bone marrow and peripheral blood prior to autologous stem cell transplant predicts better progression-free survival and overall survival in younger patients with mantle cell lymphoma.